Original from: Orasure OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has received Eme..

Original from: PR Newswire NanoSomiX, Inc., a biotechnology company focused on blood‑based analytics using extracellular vesicles (EVs), including brain‑derived EVs, today announced plans to c..

Original from: PR Newswire Seegene, Inc. ("Seegene"), a global leader in molecular diagnostics, announced today that its U.S. subsidiary, Seegene USA, Inc. ("Seegene USA"), has received an Emergency Use ..

Original from: Danaher Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons..

2.2 Products and Technology Innovation of Urine Dry Chemical Analysis 2.2.1 UC-1800 Automatic Urine Analyzer It is a new generation of products produced by URIT, which has fast testing speed, stabl..

Original from: Tempus Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive ..

Roche Diagnostics Receives NMPA Approval for Ionify Vitamin D Test Kit Roche Diagnostics announced that its Ionify® 25-Hydroxy Vitamin D Assay based on liquid chromatography-tandem mas..

Original from: business wire Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH. DISQVER® enables me..

Original from: Abbott Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026. - Second-quarter sales increased 13.0 percent on a reported basis and ..

Original from: business wire Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license ..

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and Scotland.

Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’s PD‑1‑targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution.

Only taking urine dry chemistry and urine formed element as the basic detection of urine routine is still insufficient in the diagnosis and differential diagnosis of urinary system diseases. At present, the new combin..

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it introduces the cobas® HDV test for use on the cobas® 5800/6800/8800 systems, a diagnostic tool for the detection and quantification of Hepatitis D Virus (HDV) RNA, in countries accepting the CE mark. Available on the industry-leading cobas 5800/6800/8800 systems, Roche aims to help healthcare providers in identifying patients and monitoring their care more effectively alongside newly available treatments.